Theravance Biopharma TBPH Interest Accretion On Future Royalty Payment Contingencies
Interest Accretion On Future Royalty Payment Contingencies at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept tbph:InterestAccretionOnFutureRoyaltyPaymentContingencies.
The official record: Theravance Biopharma’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's interest accretion on future royalty payment contingencies.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's interest accretion on future royalty payment contingencies?
- Theravance Biopharma (TBPH) reported interest accretion on future royalty payment contingencies of $582K in Q4 2025.
- How has Theravance Biopharma's interest accretion on future royalty payment contingencies changed year-over-year?
- Theravance Biopharma's interest accretion on future royalty payment contingencies decreased by 9.5% year-over-year, from $643K to $582K.
- What is the long-term trend for Theravance Biopharma's interest accretion on future royalty payment contingencies?
- Over 2 years (2023 to 2025), Theravance Biopharma's interest accretion on future royalty payment contingencies has grown at a 2.3% compound annual growth rate (CAGR), from $2.35M to $2.46M.
- What does interest accretion on future royalty payment contingencies mean?
- This reflects the non-cash interest expense recognized over time to adjust the present value of future contingent royalty obligations. It represents the cost of financing associated with long-term payment commitments tied to future revenue streams. An increasing trend may indicate a growing liability burden related to past licensing or acquisition agreements.